A Phase 4 interventional study of Ketamine-Assisted Psychotherapy (KAP) in Depression, Anxiety and Post Traumatic Stress Disorder, sponsored by Field Trip Health. Completed at 11 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.
Sponsored by Field Trip Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,713 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.
Among the 3,713 studies in Depression with a site in United States, this one is the 68th largest by enrollment of the 3,320 interventional ones that give a count, is one of 155 that started in 2020, is one of 265 in phase 4, and was the 2,895th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →582 of the 3,713 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 13+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,713 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 155 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,806 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 72 across the 3,320 interventional studies, 138 across the 371 observational. Of the 2,762 that completed or were terminated, 1,045 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,713 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Field Trip Health as lead sponsor.
Field Trip Health has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
299 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 299 to your calendar (.ics) → With an account.
Among the 3,713 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post traumatic stress, that would be detectable up to 6 months after treatment. The results of this study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.
Background: Ketamine-Assisted Psychotherapy (KAP) has shown positive effects within clinical trial settings and over short-term follow-ups, but sustained effects in real-world treatment settings remain unclear. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health issues. We hypothesized that there would be significant reductions in psychological distress over time.
Objective: To examine treatment effects at 1, 3, and 6 months relative to baseline on depression, anxiety, and post traumatic stress outcomes.
Design: A retrospective intervention-only effectiveness trial.
Setting: KAP was administered across 11 Field Trip Health clinics in North America. Intervention: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
Outcomes: Self-reported measures of symptoms of depression, anxiety, and post traumatic stress at 1, 3, and 6 months.
Statistical Analysis: Analyses were by intention to treat. Main analysis was a mixed linear model or growth curve model to estimate change over time per outcome, yielding estimates of mean changes at each endpoint relative to baseline. Secondary analyses included evaluating case reductions (identified by cut-off values) and minimal clinically important differences (MCIDs) at each endpoint relative to baseline.
Significance: This study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant women and nursing mothers
--Note that Post Partum Depression (PPD) can be considered on a case-by-case basis in consultation with the National Medical Director.
Any individual who has met DSM 5 criteria for a Substance Use Disorder in the past 3 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients coping with symptoms of depression, anxiety, and post traumatic stress
Combination Product: Ketamine-Assisted Psychotherapy (KAP)
KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
9-item Patient Health Questionnaire (PHQ-9)
Self-reported measure of depression, ranging from 0-27. Higher scores are worse.
Time frame: Change from 3 months compared to baseline
7-item Generalized Anxiety Disorder Measure (GAD-7)
Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.
Time frame: Change from 3 months compared to baseline
6-item PTSD Checklist (PCL-6)
Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.
Time frame: Change from 3 months compared to baseline
9-item Patient Health Questionnaire (PHQ-9)
Self-reported measure of depression, ranging from 0-27.
Time frame: Change from 1 month compared to baseline
9-item Patient Health Questionnaire (PHQ-9)
Self-reported measure of depression, ranging from 0-27.
Time frame: Change from 6 months compared to baseline
7-item Generalized Anxiety Disorder Measure (GAD-7)
Self-reported measure of anxiety, ranging from 0-21.
Time frame: Change from 1 month compared to baseline
7-item Generalized Anxiety Disorder Measure (GAD-7)
Self-reported measure of anxiety, ranging from 0-21.
Time frame: Change from 6 months compared to baseline
6-item PTSD Checklist (PCL-6)
Self-reported measure of post traumatic stress, ranging from 6-30.
Time frame: Change from 1 month compared to baseline
6-item PTSD Checklist (PCL-6)
Self-reported measure of post traumatic stress, ranging from 6-30.
Time frame: Change from 6 months compared to baseline
| Milestone | Clients |
|---|---|
| Started | 1806 |
| Completed | 94 |
| Not completed | 1712 |
Self-reported measure of depression, ranging from 0-27. Higher scores are worse.
| units on a scale | Clients |
|---|---|
| 9-item Patient Health Questionnaire (PHQ-9) | -3.23 (-3.57 to -2.90) |
Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.
| units on a scale | Clients |
|---|---|
| 7-item Generalized Anxiety Disorder Measure (GAD-7) | -4.80 (-5.17 to -4.44) |
Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.
| units on a scale | Clients |
|---|---|
| 6-item PTSD Checklist (PCL-6) | -4.24 (-4.60 to -3.87) |
Self-reported measure of depression, ranging from 0-27.
| units on a scale | Clients |
|---|---|
| 9-item Patient Health Questionnaire (PHQ-9) | -3.23 (-3.57 to -2.90) |
Self-reported measure of depression, ranging from 0-27.
| units on a scale | Clients |
|---|---|
| 9-item Patient Health Questionnaire (PHQ-9) | -4.74 (-5.68 to -3.80) |
Self-reported measure of anxiety, ranging from 0-21.
| units on a scale | Clients |
|---|---|
| 7-item Generalized Anxiety Disorder Measure (GAD-7) | -2.65 (-2.95 to -2.34) |
Self-reported measure of anxiety, ranging from 0-21.
| units on a scale | Clients |
|---|---|
| 7-item Generalized Anxiety Disorder Measure (GAD-7) | -4.10 (-5.02 to -3.18) |
Self-reported measure of post traumatic stress, ranging from 6-30.
| units on a scale | Clients |
|---|---|
| 6-item PTSD Checklist (PCL-6) | -2.14 (-2.44 to -1.83) |
Self-reported measure of post traumatic stress, ranging from 6-30.
| units on a scale | Clients |
|---|---|
| 6-item PTSD Checklist (PCL-6) | -3.44 (-4.38 to -2.50) |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clients | 0/1,806 (0%) | 0/1,806 (0%) | 0/1,806 (0%) |
| Age, Continuous(years) | Clients |
|---|---|
| Mean | 42 ± 12 |
| Sex/Gender, Customized(Participants) | Clients |
|---|---|
| Gender — Female | 948 |
| Gender — Male | 850 |
| Gender — Non-binary | 8 |
| Race/Ethnicity, Customized(Participants) | Clients |
|---|---|
| Race/Ethnicity — White | 1309 |
| Race/Ethnicity — Other Groups | 441 |
| Race/Ethnicity — Missing | 56 |
| Region of Enrollment(Participants) | Clients |
|---|---|
| North America | 1806 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Jun 2022, 27 months.
Results were first posted in May 2023, 10 months after primary completion.
Of 119 phase 4 interventional studies under Depression, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.